Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab + trastuzumab + docetaxel vs placebo + trastuzumab + docetaxel in first-line HER2-positive metastatic breast cancer (China)
CTR20160366Phase 3Completed
- Sponsor
- Roche
- Start
- Aug 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of pertuzumab in HER2-enriched breast cancer (HER2+), sponsored by Roche. Started Aug 2016; status: completed.
02
Drugs
pertuzumab
03
Conditions
HER2-enriched breast cancer (HER2+)
Beyond the preview
Go deeper on CTR20160366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160366.